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March 2012886 Abstractspreferential use of CEA in the symptomatic patient to minimize the risk of
adverse neurologic outcome.
Low Prevalence of Abdominal Aortic Aneurysm Among 65-Year-Old
Swedish Men Indicates a Change in the Epidemiology of the Disease
Svensjö S, BjörckM,GürtelschmidM, et al. Circulation 2011;124:1118-23.
Conclusions: There is a lower than expected prevalence of abdominal
aortic aneurysm (AAA) in Swedish men, likely explained by a reduction in
the prevalence of smoking. Changes in the epidemiology of AAA call into
question current abdominal aortic screening algorithms.
Summary: A common recommendation for a screening protocol for
AAA is a one-time ultrasound screening of 65-year-old men. In Sweden,
there has been a rapid introduction of such screening programs (Wanhainen
A, J Vasc Surg 2011;53:1164-5). By 2009, screening programs had been
implemented in five contiguous counties of central Sweden. Every 3months,
65-year-old men in these counties are identified by using a national popu-
lation registry and are then invited to a one-time ultrasound examination of
the abdominal aorta. In 2009, these five counties comprised 15% of Swe-
den’s population (1,404,978 individuals).
In this study, the authors report their results of screening 65-year-old
men for AAA in middle Sweden. All 65-year-old men (n  26,256) in the
five-county area of middle Sweden were identified through a national
population registry and were invited for an ultrasound examination of the
abdominal aorta. An AAA was defined as a maximum infrarenal aortic
diameter 30 mm. Of the 22,187 invited for the screening, 85% accepted
the invitation and 373 AAAs (1.7%, 95% CI, 1.5%-1.9%) were detected. If
one included 127 previously knownAAAs repaired or under surveillance, the
total prevalence of AAA in the population was 2.2% (95% CI, 2.0%-2.4%).
Independent associations from a multivariate logistic regression model with
AAA were self-reported smoking (OR, 3.4; P  .001), coronary artery
disease (OR, 2.0; P  .001), and hypertension (OR, 1.6; P  .001). In the
five-county population, 13% of inhabitants were self-reported to be current
smokers, one-third the frequency reported in the 1980s.
Comment: The population-based study design and high participation
in the screening program (85%) suggests the results of this study are
generally applicable at least to the Swedish population. The prevalence of the
AAA in this study is one-half to one-third of that reported elsewhere and
parallels a dramatic reduction in the prevalence of smoking. The decreased
prevalence of smoking combined with the significant increase in life expec-
tancy of the male population at risk for AAA has implications for AAA
screening programs. On the basis of what is apparently a decreased preva-
lence of disease and decreased risk factors, cost-effectiveness and protocols of
current screening programs may need to be reevaluated.
Nonoperative Management of Adult Blunt Splenic Injury With and
Without Splenic Artery Embolotherapy: A Meta-Analysis
Requarth JA, D’Agostino RB Jr, Miller PR. J Trauma 2011;71:898-903.
Conclusion: Embolization of splenic injury improves the result of
nonoperative management of patients with grade 4 and 5 splenic injuries.
Summary: Nonoperative management of blunt splenic injury (BSI) is
standard of care in hemodynamically stable children (Davis KA, et al,
J Trauma 1998;44:1008-13) and is also frequently used in adults. Nonop-
erative management of BSI can be observational without splenic emboliza-
tion or observational with splenic embolization. The relative effectiveness of
these two approaches stratified for grade of splenic injury is unknown.
Complicating previous studies of the effectiveness of splenic embolization
for treatment of BSI is that purely observational nonoperative management
of BSI is frequently reported along with embolic therapy for splenic injury,
but these are clearly different modes of treatment. The authors point out
that important information comparing the effectiveness of these two forms
of nonoperative management may be lost when the two forms of nonopera-
tive management are studied together or without respect to the specific
grade of splenic injury. This meta-analysis was performed to evaluate the
failure rate of adults with BSI treated with observational management only vs
splenic embolization in patients with comparable grades of injury to the
spleen. The authors reviewed 33 articles on outcomes of BSI published
between 1994 and 2009. Nine publications stratified data by splenic injury
grade for observational management and splenic embolization. The data
from these nine studies were used to analyze failure rates of pure observa-
tional management vs splenic embolization using random effects estimates.
The study comprised 10,157 patients, of whom 68.4% were managed
nonoperatively. The failure rate for nonoperative management was 8.3%
(95% CI, 6.7%-10.2%). The failure rate for observational management alone
increased from 4.7% to 83.1% in patients with splenic injury grades from 1 to
5. The failure rate of splenic embolization was 15.7% (95% CI, 10.4%-
23.2%) and did not vary significantly with splenic injury grades 4 to 5 (P 
.413). In patients with splenic injury grade injuries 4 and 5, the failure rate
of purely observational management without embolization was higher than
failure rates with embolization: 43.7% (95% CI, 25.5%-63.8%) vs 17.3% m95% CI, 7.8%-34.1%, P  .035) and 83.1% (95% CI, 45.2%-96.7%) vs
5.0% (95% CI, 8.7%-53.8%, P  .016), respectively.
Comment: The authors of this study point out that observational
anagement alone and splenic embolization are different methods of non-
perative management of patients with BSI. Comparative information can
e lost when failure rates of the two methods are combined in a single
nalysis. The data here suggest that patients with high-grade splenic injuries
grades 4 and 5) should be treated with embolization if nonoperative
anagement of BSI is chosen.
econdary Prevention and Mortality in Peripheral Artery Disease:
ational Health and Nutrition Examination Study, 1999 to 2004
ande RT, Perlstein TS, Beckman JA, et al. Circulation 2011;124:17-23.
Conclusion: Millions of adults in the U.S. do not receive secondary
reventive therapies for peripheral artery disease (PAD). In patients with
AD, treatment with multiple therapies is associated with reduced all-cause
ortality.
Summary: Lack of evidence for screening-guided treatment in patients
ith PAD has led the U.S. Preventative Services Task Force (USPSFT) to
ecommended against screening for PAD with ankle-brachial index (ABI;
nn Intern Med 2009;151:474-82). This stance has been strengthened by
ecent studies questioning the efficacy of preventive therapies in patients
ith PAD (Berger JS, et al, JAMA 2009;301:1909-19; Fowkes FG, et al,
AMA 2010;303:841-8). Guidelines for management of patients with PAD
ecommend lipid-lowering therapy with a statin, antihypertensive therapy to
chieve a systolic blood pressure 140 mm Hg, particularly angiotensin-
onverting enzyme (ACE) inhibitors, and antiplatelet therapy (Yusuf S, et al,
Engl J Med 2000;342:145-53). Because of inconsistencies for recom-
endations for secondary prevention in patients with PAD, the authors
ought to determine whether treatment with multiple risk factor-modifying
herapies was associated with reduced all-cause mortality in adults identified
ith PAD who otherwise had no established cardiovascular disease. The
uthors analyzed data from the National Health and Nutrition Examination
urvey (NHANES) from 1999 to 2004. Mortality follow-up extended
hrough calendar year 2006. PAD was defined as an ABI 0.90. In the
HANES study, there were 7458 eligible participants aged 40 years with
weighted PAD preference of 5.9%  0.3%. This equates to 7.1 million
dults in the U.S. with PAD. In the NHANES patients, statin use prevalence
as 30.5%  2.5%, ACE inhibitor/angiotensin receptor blocker (ARB) use
revalence was 24.9% 1.9 %, and aspirin use prevalence was 35.8% 2.9%.
his corresponds to 5 million adults in the U.S. with PAD not taking statins,
.4 million not taking ACE inhibitors/ARBs, and 4.5 million not receiving
spirin. Even adjusting for sex, age, and race/ethnicity, PAD was associated
ith all-cause mortality (HR, 2.4; 95% CI, 1.9-2.9; P  .0001). When
ndividuals with PAD were stratified by excluding those with known cardio-
ascular disease, PAD patients still had higher mortality rates of 16.1% 
.1% vs 4.1%  0.3% in subjects without PAD or cardiovascular disease
adjusted HR, 1.9; 95% CI, 1.3-2.8; P  .001). Multiple preventative
herapies in PAD patients without cardiovascular disease were associated
ith 65% lower all-cause mortality (HR, 0.35; 95% CI 0.20-0.86; P .02).
Comment: NHANES is a series of surveys conducted by the National
enter for Health Statistics. The surveys began in the early 1960s; from
999 to 2004, ABI measurements were added. Extrapolating to the U.S.
opulation, potentially thousands of deaths could be avoided if secondary
revention therapies were applied and adhered to in patients with PAD. The
uthors call for a large-scale clinical trial to determine whether implementa-
ion of secondary preventative therapies in patients with PAD identified by
ow ABI can indeed reduce cardiovascular morbidity and mortality. This is
ery reasonable.
upervised Exercise Versus Primary Stenting for Claudication Result-
ng From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes
rom the Claudication: Exercise Versus Endoluminal Revasculariza-
ion (CLEVER) Study
urphy TP, Cutlip DE, Regensteiner JG, et al; and the Clever Study
nvestigators. Circulation 2012;125:130-9.
Conclusion: In patients with intermittent claudication and aortoiliac
isease (AIOD), supervised exercise results in better treadmill walking
erformance than stent revascularization.
Summary: Although drug therapy, revascularization, and supervised
xercise are all documented effective therapies for intermittent claudication,
he relative effectiveness of these measures are unknown. No multicenter
linical trials have directly compared strategies of pharmacology alone or
upervised exercise vs endovascular intervention. The CLEVER trial was a
andomized clinical trial comparing the benefits of optimal medical care,
upervised exercise, and stent revascularization on walking outcomes and
easures of quality of life in patients with intermittent claudication second-
ry to AIOD.The study randomized 111 patients with AIOD to receive optimal
edical care, optimal medical care plus stent revascularization, or optimal
